SARTORIUS STEDIM BIOTECH (56S1.DE) Stock Fundamental Analysis
Europe - Frankfurt Stock Exchange - FRA:56S1 - FR0013154002 - Common Stock
209.9 EUR
+0.7 (+0.33%)
56S1 gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 19 industry peers in the Life Sciences Tools & Services industry. 56S1 has an average financial health and profitability rating. 56S1 is valued quite expensive, but it does show an excellent growth.
1. Profitability
1.1 Basic Checks
56S1 had positive earnings in the past year.
56S1 had a positive operating cash flow in the past year.
Each year in the past 5 years 56S1 has been profitable.
In the past 5 years 56S1 always reported a positive cash flow from operatings.
1.2 Ratios
56S1 has a Return On Assets of 3.35%. This is in the lower half of the industry: 56S1 underperforms 63.16% of its industry peers.
With a Return On Equity value of 6.54%, 56S1 perfoms like the industry average, outperforming 42.11% of the companies in the same industry.
56S1 has a Return On Invested Capital (5.94%) which is comparable to the rest of the industry.
The Average Return On Invested Capital over the past 3 years for 56S1 is in line with the industry average of 9.26%.
The 3 year average ROIC (10.41%) for 56S1 is well above the current ROIC(5.94%). The reason for the recent decline needs to be investigated.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.35% | ||
| ROE | 6.54% | ||
| ROIC | 5.94% |
ROA(3y)7.81%
ROA(5y)9.13%
ROE(3y)17.3%
ROE(5y)20.06%
ROIC(3y)10.41%
ROIC(5y)14.57%
1.3 Margins
With a Profit Margin value of 8.96%, 56S1 perfoms like the industry average, outperforming 57.89% of the companies in the same industry.
56S1's Profit Margin has declined in the last couple of years.
The Operating Margin of 56S1 (16.63%) is better than 63.16% of its industry peers.
In the last couple of years the Operating Margin of 56S1 has declined.
With a decent Gross Margin value of 45.64%, 56S1 is doing good in the industry, outperforming 68.42% of the companies in the same industry.
56S1's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 16.63% | ||
| PM (TTM) | 8.96% | ||
| GM | 45.64% |
OM growth 3Y-22.38%
OM growth 5Y-9.98%
PM growth 3Y-24.01%
PM growth 5Y-17.3%
GM growth 3Y-6.9%
GM growth 5Y-3.53%
2. Health
2.1 Basic Checks
56S1 has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
Compared to 1 year ago, 56S1 has more shares outstanding
The number of shares outstanding for 56S1 has been increased compared to 5 years ago.
The debt/assets ratio for 56S1 has been reduced compared to a year ago.
2.2 Solvency
56S1 has an Altman-Z score of 4.48. This indicates that 56S1 is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 4.48, 56S1 belongs to the top of the industry, outperforming 84.21% of the companies in the same industry.
The Debt to FCF ratio of 56S1 is 6.84, which is on the high side as it means it would take 56S1, 6.84 years of fcf income to pay off all of its debts.
Looking at the Debt to FCF ratio, with a value of 6.84, 56S1 is in line with its industry, outperforming 47.37% of the companies in the same industry.
A Debt/Equity ratio of 0.50 indicates that 56S1 is not too dependend on debt financing.
56S1 has a Debt to Equity ratio (0.50) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.5 | ||
| Debt/FCF | 6.84 | ||
| Altman-Z | 4.48 |
ROIC/WACC0.64
WACC9.26%
2.3 Liquidity
56S1 has a Current Ratio of 1.05. This is a normal value and indicates that 56S1 is financially healthy and should not expect problems in meeting its short term obligations.
56S1's Current ratio of 1.05 is on the low side compared to the rest of the industry. 56S1 is outperformed by 68.42% of its industry peers.
A Quick Ratio of 0.50 indicates that 56S1 may have some problems paying its short term obligations.
56S1's Quick ratio of 0.50 is on the low side compared to the rest of the industry. 56S1 is outperformed by 78.95% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.05 | ||
| Quick Ratio | 0.5 |
3. Growth
3.1 Past
56S1 shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 35.11%, which is quite impressive.
The Earnings Per Share has been growing slightly by 4.19% on average over the past years.
The Revenue has been growing slightly by 7.72% in the past year.
The Revenue has been growing by 14.05% on average over the past years. This is quite good.
EPS 1Y (TTM)35.11%
EPS 3Y-22.3%
EPS 5Y4.19%
EPS Q2Q%23.68%
Revenue 1Y (TTM)7.72%
Revenue growth 3Y-1.25%
Revenue growth 5Y14.05%
Sales Q2Q%7.67%
3.2 Future
56S1 is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 22.11% yearly.
The Revenue is expected to grow by 10.12% on average over the next years. This is quite good.
EPS Next Y29.39%
EPS Next 2Y23.86%
EPS Next 3Y23.06%
EPS Next 5Y22.11%
Revenue Next Year7.45%
Revenue Next 2Y8.04%
Revenue Next 3Y9.07%
Revenue Next 5Y10.12%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 48.70, which means the current valuation is very expensive for 56S1.
Based on the Price/Earnings ratio, 56S1 is valued a bit more expensive than 78.95% of the companies in the same industry.
When comparing the Price/Earnings ratio of 56S1 to the average of the S&P500 Index (26.60), we can say 56S1 is valued expensively.
56S1 is valuated quite expensively with a Price/Forward Earnings ratio of 39.09.
78.95% of the companies in the same industry are cheaper than 56S1, based on the Price/Forward Earnings ratio.
Compared to an average S&P500 Price/Forward Earnings ratio of 23.23, 56S1 is valued quite expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 48.7 | ||
| Fwd PE | 39.09 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of 56S1 indicates a rather expensive valuation: 56S1 more expensive than 84.21% of the companies listed in the same industry.
The rest of the industry has a similar Price/Free Cash Flow ratio as 56S1.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 54.55 | ||
| EV/EBITDA | 28.02 |
4.3 Compensation for Growth
The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
A more expensive valuation may be justified as 56S1's earnings are expected to grow with 23.06% in the coming years.
PEG (NY)1.66
PEG (5Y)11.61
EPS Next 2Y23.86%
EPS Next 3Y23.06%
5. Dividend
5.1 Amount
With a yearly dividend of 0.34%, 56S1 is not a good candidate for dividend investing.
56S1's Dividend Yield is slightly below the industry average, which is at 0.60.
With a Dividend Yield of 0.34, 56S1 pays less dividend than the S&P500 average, which is at 2.00.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.34% |
5.2 History
The dividend of 56S1 has a limited annual growth rate of 4.44%.
Dividend Growth(5Y)4.44%
Div Incr Years0
Div Non Decr Years1
5.3 Sustainability
56S1 pays out 25.41% of its income as dividend. This is a sustainable payout ratio.
56S1's earnings are growing more than its dividend. This makes the dividend growth sustainable.
DP25.41%
EPS Next 2Y23.86%
EPS Next 3Y23.06%
FRA:56S1 (1/2/2026, 7:00:00 PM)
209.9
+0.7 (+0.33%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners11.74%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap20.43B
Revenue(TTM)2.95B
Net Income(TTM)264.10M
Analysts81.11
Price Target240.69 (14.67%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.34% |
Yearly Dividend0.71
Dividend Growth(5Y)4.44%
DP25.41%
Div Incr Years0
Div Non Decr Years1
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)3.99%
Min EPS beat(2)-2.24%
Max EPS beat(2)10.22%
EPS beat(4)3
Avg EPS beat(4)9.45%
Min EPS beat(4)-2.24%
Max EPS beat(4)22.18%
EPS beat(8)3
Avg EPS beat(8)-1.58%
EPS beat(12)3
Avg EPS beat(12)-11.08%
EPS beat(16)4
Avg EPS beat(16)-13.1%
Revenue beat(2)1
Avg Revenue beat(2)-1.82%
Min Revenue beat(2)-3.94%
Max Revenue beat(2)0.3%
Revenue beat(4)3
Avg Revenue beat(4)0.7%
Min Revenue beat(4)-3.94%
Max Revenue beat(4)3.52%
Revenue beat(8)5
Avg Revenue beat(8)-0.23%
Revenue beat(12)5
Avg Revenue beat(12)-1.54%
Revenue beat(16)7
Avg Revenue beat(16)-0.72%
PT rev (1m)0.77%
PT rev (3m)0.51%
EPS NQ rev (1m)4.24%
EPS NQ rev (3m)14.4%
EPS NY rev (1m)0.86%
EPS NY rev (3m)1.39%
Revenue NQ rev (1m)-0.08%
Revenue NQ rev (3m)0.03%
Revenue NY rev (1m)-1.38%
Revenue NY rev (3m)-2.76%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 48.7 | ||
| Fwd PE | 39.09 | ||
| P/S | 6.93 | ||
| P/FCF | 54.55 | ||
| P/OCF | 27.96 | ||
| P/B | 5.06 | ||
| P/tB | N/A | ||
| EV/EBITDA | 28.02 |
EPS(TTM)4.31
EY2.05%
EPS(NY)5.37
Fwd EY2.56%
FCF(TTM)3.85
FCFY1.83%
OCF(TTM)7.51
OCFY3.58%
SpS30.27
BVpS41.47
TBVpS-4.02
PEG (NY)1.66
PEG (5Y)11.61
Graham Number63.42
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.35% | ||
| ROE | 6.54% | ||
| ROCE | 7.46% | ||
| ROIC | 5.94% | ||
| ROICexc | 6.26% | ||
| ROICexgc | 21.64% | ||
| OM | 16.63% | ||
| PM (TTM) | 8.96% | ||
| GM | 45.64% | ||
| FCFM | 12.71% |
ROA(3y)7.81%
ROA(5y)9.13%
ROE(3y)17.3%
ROE(5y)20.06%
ROIC(3y)10.41%
ROIC(5y)14.57%
ROICexc(3y)10.84%
ROICexc(5y)15.37%
ROICexgc(3y)26.31%
ROICexgc(5y)36.49%
ROCE(3y)13.07%
ROCE(5y)18.3%
ROICexgc growth 3Y-36.77%
ROICexgc growth 5Y-16.49%
ROICexc growth 3Y-43.34%
ROICexc growth 5Y-25.09%
OM growth 3Y-22.38%
OM growth 5Y-9.98%
PM growth 3Y-24.01%
PM growth 5Y-17.3%
GM growth 3Y-6.9%
GM growth 5Y-3.53%
F-Score8
Asset Turnover0.37
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.5 | ||
| Debt/FCF | 6.84 | ||
| Debt/EBITDA | 2.5 | ||
| Cap/Depr | 113.12% | ||
| Cap/Sales | 12.09% | ||
| Interest Coverage | 3.09 | ||
| Cash Conversion | 90.78% | ||
| Profit Quality | 141.8% | ||
| Current Ratio | 1.05 | ||
| Quick Ratio | 0.5 | ||
| Altman-Z | 4.48 |
F-Score8
WACC9.26%
ROIC/WACC0.64
Cap/Depr(3y)182.98%
Cap/Depr(5y)186.68%
Cap/Sales(3y)13.87%
Cap/Sales(5y)12.23%
Profit Quality(3y)126.76%
Profit Quality(5y)109.63%
High Growth Momentum
Growth
EPS 1Y (TTM)35.11%
EPS 3Y-22.3%
EPS 5Y4.19%
EPS Q2Q%23.68%
EPS Next Y29.39%
EPS Next 2Y23.86%
EPS Next 3Y23.06%
EPS Next 5Y22.11%
Revenue 1Y (TTM)7.72%
Revenue growth 3Y-1.25%
Revenue growth 5Y14.05%
Sales Q2Q%7.67%
Revenue Next Year7.45%
Revenue Next 2Y8.04%
Revenue Next 3Y9.07%
Revenue Next 5Y10.12%
EBIT growth 1Y25.54%
EBIT growth 3Y-23.35%
EBIT growth 5Y2.67%
EBIT Next Year93.64%
EBIT Next 3Y36.06%
EBIT Next 5Y27.7%
FCF growth 1Y219.27%
FCF growth 3Y7.94%
FCF growth 5Y22.24%
OCF growth 1Y15.97%
OCF growth 3Y5.11%
OCF growth 5Y21.32%
SARTORIUS STEDIM BIOTECH / 56S1.DE FAQ
What is the ChartMill fundamental rating of SARTORIUS STEDIM BIOTECH (56S1.DE) stock?
ChartMill assigns a fundamental rating of 4 / 10 to 56S1.DE.
Can you provide the valuation status for SARTORIUS STEDIM BIOTECH?
ChartMill assigns a valuation rating of 1 / 10 to SARTORIUS STEDIM BIOTECH (56S1.DE). This can be considered as Overvalued.
How profitable is SARTORIUS STEDIM BIOTECH (56S1.DE) stock?
SARTORIUS STEDIM BIOTECH (56S1.DE) has a profitability rating of 5 / 10.
Can you provide the PE and PB ratios for 56S1 stock?
The Price/Earnings (PE) ratio for SARTORIUS STEDIM BIOTECH (56S1.DE) is 48.7 and the Price/Book (PB) ratio is 5.06.
What is the earnings growth outlook for SARTORIUS STEDIM BIOTECH?
The Earnings per Share (EPS) of SARTORIUS STEDIM BIOTECH (56S1.DE) is expected to grow by 29.39% in the next year.